Omnicell (NASDAQ:OMCL) Updates FY20 Earnings Guidance

Omnicell (NASDAQ:OMCL) issued an update on its FY20 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of $2.46-2.51 for the period, compared to the Thomson Reuters consensus estimate of $2.38. The company issued revenue guidance of $890-892 million, compared to the consensus revenue estimate of $884.29 million.Omnicell also updated its FY 2020
Pre-Market guidance to 2.46-2.51 EPS.

Shares of NASDAQ:OMCL opened at $120.94 on Wednesday. The company has a market capitalization of $5.12 billion, a price-to-earnings ratio of 107.03, a price-to-earnings-growth ratio of 3.55 and a beta of 0.83. Omnicell has a 52 week low of $54.24 and a 52 week high of $125.00. The firm has a 50 day moving average of $114.64 and a 200 day moving average of $85.59.

Omnicell (NASDAQ:OMCL) last announced its earnings results on Tuesday, October 27th. The company reported $0.60 EPS for the quarter, topping the Zacks’ consensus estimate of $0.31 by $0.29. Omnicell had a net margin of 5.42% and a return on equity of 9.21%. The business had revenue of $213.70 million during the quarter, compared to the consensus estimate of $208.71 million. As a group, equities analysts anticipate that Omnicell will post 1.5 earnings per share for the current fiscal year.

Several research analysts recently issued reports on the company. Wells Fargo & Company upped their target price on Omnicell from $74.00 to $84.00 and gave the company an equal weight rating in a research report on Wednesday, October 28th. BidaskClub raised shares of Omnicell from a buy rating to a strong-buy rating in a research report on Tuesday, October 27th. Piper Sandler upped their price target on shares of Omnicell from $70.00 to $86.00 and gave the company a neutral rating in a research note on Wednesday, October 28th. Cantor Fitzgerald downgraded shares of Omnicell from an overweight rating to a neutral rating and set a $95.00 price objective for the company. in a research note on Thursday, December 3rd. They noted that the move was a valuation call. Finally, Benchmark upped their target price on Omnicell from $100.00 to $125.00 and gave the company a buy rating in a research report on Wednesday, December 9th. Four investment analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of Buy and an average target price of $97.14.

In other news, CEO Randall A. Lipps sold 17,500 shares of the business’s stock in a transaction dated Tuesday, December 8th. The shares were sold at an average price of $110.56, for a total transaction of $1,934,800.00. Following the completion of the sale, the chief executive officer now owns 152,116 shares of the company’s stock, valued at $16,817,944.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Robin Gene Seim sold 1,319 shares of the firm’s stock in a transaction dated Monday, January 4th. The shares were sold at an average price of $119.62, for a total transaction of $157,778.78. Following the completion of the transaction, the director now directly owns 36,877 shares in the company, valued at $4,411,226.74. The disclosure for this sale can be found here. Insiders have sold 47,654 shares of company stock valued at $4,949,164 over the last 90 days. 2.63% of the stock is currently owned by insiders.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management automation solutions and adherence tools for healthcare systems and pharmacies worldwide. The company offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems.

Featured Article: What are the Benefits of Index Funds?